|
Ostroumova O.D., Telkova S.S., Dubinina A.V., Klepikova M.V., Kochetkov A.I.
Non-alcoholic fatty liver disease as a trigger of polymorbidity. Is there a way out of the impasse?
|
№4 / 2024
|
|
Davidenko I.Yu., Volkova N.I., Degtyareva Yu.S.
Treatment options for different subtypes of gestational diabetes
|
№2 / 2024
|
|
N.I. Volkova, I.Yu. Davidenko, Yu.S. Degtyareva, V.V. Avrutskaya, Yu.A. Sorokina, V.N. Kovalenko
Biochemical markers of various subtypes of gestational diabetes
|
№12 / 2023
|
|
O.A. Pustotina
Polycystic ovary syndrome phenotypes
|
№4-5 / 2023
|
|
L.A. Ruyatkina, D.S. Ruyatkin, L.V. Shcherbakova
Age-dependent aspects of informativeness of surrogate indices of insulin resistance in the formation of menopausal metabolic syndrome
|
№3 / 2023
|
|
N.V. Kazachenko (1), V.V. Platonov (1–3), M.E. Turkunova (3), Yu.L. Skorodok (3), E.Yu. Smirnova (4)
Progeroid syndrome caused by a defect in the WRN gene. Description of a clinical case in a teenager
|
№12 / 2021
|
|
N.I. Volkova, S.O. Panenko, A.O. Golubeva
Is non-alcoholic fatty liver disease a consequence of obesity and a predictor of diabetes?
|
№12 / 2021
|
|
A.F. Verbovoy, Yu.A. Dolgikh
Insulin resistance – a common enemy for endocrinologists and cardiologists
|
№12 / 2021
|
|
A.S. Ametov (1), E.A. Tertychnaya (2)
Early pathogenetic combined therapy of sugar diabetes type 2: focus on insulin resistance
|
№14 / 2019
|
|
E.V. Biryukova, I.V. Solovyova
Do we know everything about the possibilities of metformin in the treatment of type 2 diabetes mellitus? Which of its combinations is the most studied, effective and available for the patient in the real practice of the endocrinologist?
|
№4 / 2019
|
|
N.S. Alekseeva (1), E.V. Beloborodova (2)
The effectiveness of therapeutic measures in metabolic syndrome and vitamin d deficiency
|
№4 / 2019
|
|
A.F. Verbovoy, Yu.A. Dolgikh, O.V. Kosareva, L.A. Sharonova, I.A. Tsanava
INSULIN RESISTANCE AND THYROID HORMONES
|
№5 / 2017
|
Русский
